Qdenga | Description | MIMS Thailand

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Thai FDA Category Presentation/Packing Local Product Insert

The information highlighted (if any) are the most recent updates for this brand.

Full Prescribing Info

Description

Prior to reconstitution, the vaccine is a white to off-white colored freeze-dried powder (compact cake).
The diluent (solvent) is a clear, colorless solution.
After reconstitution, 1 dose (0.5 mL) contains Dengue virus serotype 1 (live, attenuated)*: ≥3.3 log10 PFU**/dose.
Dengue virus serotype 2 (live, attenuated)#: ≥2.7 log10 PFU**/dose.
Dengue virus serotype 3 (live, attenuated)*: ≥4.0 log10 PFU**/dose.
Dengue virus serotype 4 (live, attenuated)*: ≥4.5 log10 PFU**/dose.
*Produced in Vero cells by recombinant DNA technology. Genes of serotype-specific surface proteins engineered into dengue type 2 backbone.
#Produced in Vero cells by recombinant DNA technology.
**PFU = Plaque-forming units.
Excipients/Inactive Ingredients: Powder: α,α-Trehalose dihydrate, Poloxamer 407, Human serum albumin, Potassium dihydrogen phosphate, Disodium hydrogen phosphate, Potassium chloride, Sodium chloride.
Diluent (Solvent): Sodium chloride, Water for injections.

Qdenga Description

Manufacturer:

Takeda

Distributor:

Zuellig Pharma